Indoco Remedies Q4 Review - Strong Management Guidance, Execution Remains Key: ICICI Direct
Tablets exit a machine. (Photographer Krisztian Bocsi/Bloomberg)

Indoco Remedies Q4 Review - Strong Management Guidance, Execution Remains Key: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Indoco Remedies Ltd.'s Q4 FY21 revenue grew 12.2% YoY to Rs 305 crore.

Export formulations grew 65.6% YoY to Rs 132 crore driven by strong growth in regulated and emerging markets.

Domestic formulations de-grew 13.0% YoY to Rs 139 crore due to continued impact on anti-infective and respiratory segment.

Active pharmaceutical ingredient segment remained subdued at Rs 20 crore, down 1.5% YoY.

Ebitda margins expanded 569 basis points YoY to 17.9% on account of lower staff, travel and promotional spend partly offset by decline in gross margin performance.

Click on the attachment to read the full report:

ICICI Direct Indoco Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.